Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$2.47 USD
+0.13 (5.56%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $2.39 -0.08 (-3.24%) 7:42 PM ET
4-Sell of 5 4
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
MBRX 2.47 +0.13(5.56%)
Will MBRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MBRX
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for MBRX
Moleculin Participates in Virtual Investor "What this Means" Segment
Moleculin Biotech CEO Discusses Clinical Trials and Drug Development
Moleculin Biotech Shares Insights in Corporate Update
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference